A large proportion of asthmatics are not in control of their condition, leading to hospitalizations and missed days of work or school, as well as the large percentage of asthmatics minimizing their daily activity levels due to their asthma.1 Research has shown that both patients and physicians overestimate the level of asthma control.2 Asthma patients are commonly prescribed quick relief medication, the purpose of which is to rapidly relieve symptoms short term; quick relief medicine may help the asthmatic get through an acute episode but it does not improve the underlying inflammation that is crucial in getting persistent asthma under control.
Maximize the effectiveness of your patient’s inhaled therapies with the Philips OptiChamber Diamond valved holding chamber (spacer) to improve aerosol delivery to the lungs.
Keep track of your patient’s asthma with a PersonalBest Peak flow Meter, the easy to use peak flow monitoring device from Philips.
Fast, effective and easy to use, the InnoSpire Go portable nebulizer reduces treatment time by up to 25%3 and delivers treatment in 4 minutes4, giving your patient more time for those special moments with family and friends.
Sami the Seal, a pediatric nebulizer compressor system in the shape of a lovingly designed character. The playful seal shape and color are designed to make treatment less scary for your young patients.
Contact us to find out more or arrange an in-pharmacy visit
One of the keys to helping patients maintain control of persistent asthma is to adhere to the appropriate dosage of long term controller medication: inhaled corticosteroids (ICS). Pharmacists can contribute to this with a few simple steps which includes reviewing medications, pMDI technique, and recommending that a spacer may be necessary to maximize medication delivery and may reduce side effects of medication in throat or stomach.
Philips range of asthma management solutions can help patients and caregivers manage and control asthma.
Philips advanced aerosol devices and lab facilities offer pharmaceutical companies an in-depth level of support for every step of the development process.
1 “Asthma’s Impact on the Nation”, Data from the CDC National Asthma Control Program, accessed December 2016 2 Kenneth R Chapman, et al. “Control of asthma in Canada: Failure to achieve guideline targets.” Canadian Respiratory Journal, Volume 8, Supplement A, March/April, 2001, pp 35A – 40A researchgate.net 3 versus predecessor Aeroneb go 4 using 2.5ml salbutamol 5 Bonds R.S. Misuse of medical devices among patients in a tertiary care Allergy/Immunology practice. Journal of Allergy and Clinical Immunology, 2017, 133(3) supplement: AB156. 6 An evaluation of two aerosol delivery systems for rhDNase – PL Shah et al. ERS Journal 1997
You are about to visit a Philips global content page
Continue